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3Abstract
Objectives To develop and validate a pragmatic risk score to predict mortality in patients admitted to 
hospital with covid-19. 
Design Prospective observational cohort study: ISARIC WHO CCP-UK study (ISARIC Coronavirus Clinical 
Characterisation Consortium [4C]). Model training was performed on a cohort of patients recruited 
between 6 February and 20 May 2020, with validation conducted on a second cohort of patients 
recruited after model development between 21 May and 29 June 2020.
Setting 260 hospitals across England, Scotland, and Wales.
Participants Adult patients (≥18 years) admitted to hospital with covid-19 at least four weeks before 
final data extraction.
Main outcome measures In-hospital mortality.
Results There were 35 463 patients included in the derivation dataset (mortality rate 32.2%) and 22 361 
in the validation dataset (mortality 30.1%). The final 4C Mortality Score included eight variables readily 
available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral 
oxygen saturation, level of consciousness, urea, and C-reactive protein (score range 0-21 points). The 4C 
score demonstrated high discrimination for mortality (derivation cohort: AUROC 0.79, 95% CI 0.78-0.79; 
validation cohort 0.77, 0.76-0.77) with excellent calibration (validation: calibration-in-the-large = 0, 
slope = 1.0). Patients with a score ≥15 (n = 4158, 19%) had a 62% mortality (i.e., positive predictive value 
62%) compared with 1% mortality for those with a score ≤3 (n = 1650, 7%; negative predictive value 
98%). Discriminatory performance was higher than 15 pre-existing risk stratification scores (AUROC 
range 0.61-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-
0.73).
Conclusions We have developed and validated an easy-to-use risk stratification score based on 
commonly available parameters at hospital presentation. This outperformed existing scores, 
demonstrated utility to directly inform clinical decision making, and can be used to stratify inpatients 
with covid-19 into different management groups. The 4C Mortality Score should be further validated to 
determine its applicability in other populations. 
Study registration ISRCTN66726260
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4Introduction
Disease resulting from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
has a high mortality rate with deaths predominantly due to respiratory failure.1 As of 16 August 2020, 
there are over 21 million confirmed cases worldwide and at least 770 000 deaths.2,3 As hospitals around 
the world are faced with an influx of patients with covid-19, there is an urgent need for a pragmatic risk 
stratification tool that will allow the early identification of patients infected with SARS-CoV-2 who are at 
the highest risk of death, to guide management and optimise resource allocation. 
Prognostic scores attempt to transform complex clinical pictures into tangible numerical values. 
Prognostication is more difficult when dealing with a severe pandemic illness such as covid-19, as strain 
on healthcare resources and rapidly evolving treatments alter the risk of death over time. Early 
information has suggested that the clinical course of a patient with covid-19 is different from that of 
pneumonia, seasonal influenza, or sepsis.4 The majority of patients with severe covid-19 have developed 
a clinical picture characterised by pneumonitis, profound hypoxia, and systemic inflammation affecting 
multiple organs.1
A recent review identified many prognostic scores used for covid-19,5 which varied in their setting, 
predicted outcome measure, and the clinical parameters included. The large number of risk 
stratification tools reflects difficulties in their application, with most scores demonstrating moderate 
performance at best and no benefit to clinical decision-making.6,7 It has been found that many novel 
covid-19 prognostic scores have a high risk of bias, which may reflect development in small cohorts, and 
many have been published without clear details of model derivation and testing.5 To our knowledge, a 
risk stratification tool is yet to be developed and validated within a large national cohort of hospitalised 
patients with covid-19.
Our aim was to develop and validate a pragmatic, clinically relevant risk stratification score using 
routinely available clinical information at hospital presentation to predict in-hospital mortality in 
hospitalised covid-19 patients and then compare this with existing prognostic models.
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5Methods 
Study design and setting
The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical 
Characterisation Protocol UK (CCP-UK) study is an ongoing prospective cohort study in 260 acute care 
hospitals across England, Scotland, and Wales (National Institute for Health Research Clinical Research 
Network Central Portfolio Management System ID: 14152) performed by the ISARIC Covid-19 Clinical 
Characterisation Consortium (ISARIC-4C). The protocol and further study details are available online.8 
Model development and reporting followed the Transparent Reporting of a multivariable prediction 
model for Individual Prediction or Diagnosis (TRIPOD) guidelines.9 The study was performed according to 
a pre-defined protocol (Appendix 1).
Participants
Consecutive patients aged ≥18 years old with a completed index admission to one of 260 hospitals in 
England, Scotland, or Wales were included.8 Reverse transcriptase-PCR was the only mode of testing 
available during the period of study. The decision to test was at the discretion of the clinician attending 
the patient, and not defined by protocol. The enrolment criterion “high likelihood of infection” reflected 
that a preparedness protocol cannot assume a diagnostic test will be available for an emergent 
pathogen. In this activation, site training emphasised importance of only recruiting proven cases.
Data collection
Demographic, clinical, and outcomes data were collected using a pre-specified case report form. 
Comorbidities were defined according to a modified Charlson Comorbidity Index;10 those collected were: 
chronic cardiac disease; chronic respiratory disease (excluding asthma); chronic renal disease (estimated 
glomerular filtration rate ≤30); mild-to-severe liver disease; dementia; chronic neurological conditions; 
connective tissue disease; diabetes mellitus (diet, tablet or insulin-controlled); HIV/AIDS; and 
malignancy. These were selected a priori by a global consortium to provide rapid, coordinated clinical 
investigation of patients presenting with any severe or potentially severe acute infection of public 
interest and enabled standardisation. 
Clinician-defined obesity was also included as a comorbidity due its likely association with adverse 
outcomes in patients with covid-19.11,12 The clinical information used to calculate prognostic scores was 
taken from the day of admission to hospital.13 A practical approach was taken to sample size 
requirements.14 We used all available data to maximise the power and generalisability of our results. 
Model reliability was assessed using a temporally distinct validation cohort with geographical subsetting, 
together with sensitivity analyses. 
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Outcomes
The primary outcome was in-hospital mortality. This outcome was selected due to the importance of the 
early identification of patients likely to develop severe illness from SARS-CoV-2 infection (a ‘rule in’ test). 
We chose a priori to restrict analysis of outcomes to patients who were admitted more than four weeks 
before final data extraction (29th June 2020) to enable most patients to complete their hospital 
admission.
Independent predictor variables
A reduced set of potential predictor variables was selected a priori including patient demographic 
information, common clinical investigations, and parameters consistently identified as clinically 
important in covid-19 cohorts following methodology described by Wynants et al (Appendix 2).5 
Candidate predictor variables were selected based on three common criteria:15 (1) patient and clinical 
variables known to influence outcome in pneumonia and flu-like illness; (2) clinical biomarkers 
previously identified within the literature as potential predictors in covid-19 patients; and (3) values 
were available for at least two-thirds of patients within the derivation cohort.
With the overall aim to develop an easy-to-use risk stratification score, an a priori decision was made to 
include an overall comorbidity count for each patient within model development giving each 
comorbidity equal weight, rather than individual comorbidities. Recent evidence suggests an additive 
effect of comorbidity in covid-19 patients, with increasing number of comorbidities associated with 
poorer outcomes.16
Model development
Missing values in potential candidate variables was handled using multiple imputation by chained 
equations, under the missing at random assumption (Appendix 6). Ten sets, each with 10 iterations, 
were imputed using available explanatory variables for both cohorts (derivation and validation). The 
outcome variable was included as a predictor in the derivation but not validation dataset. All model 
derivation and validation was performed in imputed datasets, with Rubin’s rules17 used to combine 
results. 
Models were trained using all available data up to 20th May 2020. The primary intention was to create a 
pragmatic model for bedside use not requiring complex equations, online calculators, or mobile 
applications. An a priori decision was therefore made to categorise continuous variables in the final 
prognostic score. 
A three-stage model building process was used (Figure 1). Firstly, generalised additive models (GAMs) 
were built incorporating continuous smoothed predictors (penalised thin-plate splines) in combination 
with categorical predictors as linear components. A criterion-based approach to variable selection was 
taken based on the deviance explained, the unbiased risk estimator, and the area under the receiver 
operating characteristic curve (AUROC). 
7Secondly, plots of component smoothed continuous predictors were visually inspected for linearity and 
optimal cut-points were selected using the methods of Barrio et al.18
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Lastly, final models using categorised variables were specified with least absolute shrinkage and 
selection operator (LASSO) logistic regression. L1-penalised coefficients were derived using 10-fold 
cross-validation to select the value of lambda (minimised cross-validated sum of squared residuals). 
Shrunk coefficients were converted to a prognostic index with appropriate scaling to create the 
pragmatic 4C Mortality Score (where 4C stands for Coronavirus Clinical Characterisation Consortium).
Machine learning approaches were used in parallel for comparison of predictive performance. Given 
issues with interpretability, this was intended to provide a “best-in-class” comparison of predictive 
performance when accounting for any complex underlying interactions. Gradient boosting decision trees 
were used (XGBoost). All candidate predictor variables identified were included within the model, 
except for those with high missing values (>33%). Individual major comorbidity variables were retained 
within the model to determine whether inclusion improved predictive performance. An 80%/20% 
random split of the derivation dataset was used to define train/test sets. The validation datasets were 
held back and not used in the training process. A mortality label and design matrix of 
centred/standardised continuous and categorical variables including all candidate variables were used 
to train gradient boosted trees minimising the binary classification error rate (defined as number wrong 
cases / number all cases). Hyperparameters were tuned including the learning rate and maximum tree 
depth to maximise the AUROC in the test set. This approach affords flexibility in the handling of missing 
data, so two models were trained and optimised, one using imputed data and another modelling 
missingness in complete case data. 
Discrimination was assessed for all models using the AUROC in the derivation cohort, with 95% 
confidence intervals (CI) calculated using bootstrapped resampling (2000 samples). An AUROC value of 
0.5 indicates no predictive ability, 0.8 is considered good, and 1.0 is perfect.19 Overall goodness-of-fit 
was assessed with the Brier score,20 a measure to quantify how close predictions are to the truth ranging 
between 0 and 1, where smaller values indicate superior model performance. We plotted model 
calibration curves to examine agreement between predicted and observed risk across deciles of 
mortality risk to ascertain the presence of over- or under-prediction. Risk cut-off values were defined by 
the total point score for an individual which represented a low (<2% mortality rate), intermediate (2-
14.9%) or high-risk (≥15%) groups, similar to commonly used pneumonia risk stratification scores.21,22 
Sensitivity analyses were performed using complete case data. Model discrimination was also checked in 
ethnic groups and by sex using imputed datasets.
Model validation
Patients entered subsequently into the ISARIC WHO CCP-UK study after 20th May 2020 were included in 
a separate validation cohort (Figure 1). We determined discrimination, calibration, and performance 
across a range of clinically-relevant metrics. To avoid bias in the assessment of outcomes, patients who 
admitted within four weeks prior to data extraction on 29th June 2020 were excluded. Patients without 
an outcome after four weeks were included and considered to have had no event.
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A sensitivity analysis was also performed, with stratification of the validation cohort by geographical 
location. This geographical categorisation was selected based on well-described economic and health 
inequalities between the north and south of the UK.23,24 Recent analysis has demonstrated the impact of 
deprivation on risk of dying with covid-19.25 As a result, population differences between regions may 
change the discriminatory performance of risk stratification scores. Two geographical cohorts were 
created, based on north-south geographical locations across the United Kingdom as defined by Hacking 
et al.23 A further sensitivity analysis was performed to determine model performance in ethnic minority 
groups, given reported differences in covid-19 outcomes.26
All tests were two-tailed and p values <0.05 were considered statistically significant. We used R (version 
3.6.3) with the finalfit, mice, glmnet, pROC, recipes, xgboost, rmda and tidyverse packages for all 
statistical analysis.
Comparison with existing risk stratification scores
All derived models in the derivation dataset were compared within the validation cohort with existing 
scores. Model performance was assessed using the AUROC statistic, sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV). Existing risk stratification scores were 
identified through a systematic literature search of EMBASE, WHO Medicus, and Google Scholar 
databases. We used the search terms “pneumonia”, “sepsis”, “influenza”, “COVID-19”, “SARS-CoV-2”, 
“coronavirus” combined with “score”’ and “prognosis”. We applied no language or date restrictions. The 
last search was performed on 1st July 2020. Risk stratification tools were included whose variables were 
available within the database and had accessible methodology for calculation.
Performance characteristics were calculated according to original publications, and score cut-offs for 
adverse outcomes were selected based on the most commonly used criteria identified within the 
literature. Cut-offs were the score value for which the patient was considered at low- or high-risk of 
adverse outcome, as defined by study authors. Patients with one or more missing input variables were 
omitted for that particular score. 
A decision curve analysis (DCA) was also performed.27 Briefly, assessment of the adequacy of clinical 
prediction models can be extended by determining clinical utility. Using DCA, a clinical judgment of the 
relative value of benefits (treating a true positive) and harms (treating a false positive) associated with a 
clinical prediction tool can be made. The standardised net benefit was plotted against the threshold 
probability for considering a patient “high risk” for age alone and for the best discriminating models 
applicable to >50% of patients in the validation cohort. 
Patient and public involvement
This was an urgent public health research study in response to a Public Health Emergency of 
International Concern. Patients or the public were not involved in the design, conduct, or reporting of 
this rapid response research.
9Figure 1. Model derivation and validation workflow.
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10
Results
In the derivation cohort, we collected data from 35 463 patients between 6 February 2020 and 20 May 
2020. 1275 (3.6%) patients had no outcome recorded and were considered alive. The overall mortality 
was 32.2% (11 426 patients). The median age of patients in the cohort was 73 (interquartile range (IQR) 
59-83) years. 41.7% (14 741) were female and 76.0% (26 966) patients had at least one comorbidity.
Demographic and clinical characteristics for the derivation and validation datasets are shown in Table 1.
Model development
In total, 41 candidate predictor variables measured at hospital admission were identified for model 
creation (Figure 1; Appendix 2). Following the creation of a composite variable containing all seven 
individual comorbidities and the exclusion of 13 variables due to high levels of missing values, 21 
variables remained.
Generalised additive modelling (GAM) using multiply imputed datasets identified eight important 
predictors of mortality; age, sex, number of comorbidities, respiratory rate, peripheral oxygen 
saturation, Glasgow Coma Scale (GCS), urea, and C-reactive protein (CRP) (for variable selection process, 
see Appendix 3). Given the a priori need for a pragmatic score for use at the bedside, continuous 
variables were converted to factors with cut-points chosen using component smoothed functions (on 
linear predictor scale) from GAM model (Appendix 4). 
On entering variables into a penalised logistic regression model (LASSO), all variables were retained 
within the final model (Appendix 5). Penalised regression coefficients were converted into a prognostic 
index using appropriate scaling (4C Mortality Score range 0-21 points; Table 2). 
The 4C Mortality Score demonstrated good discrimination for in-patient death within the derivation 
cohort (Table 3) with performance that approached that of the XGBoost model. The 4C Mortality Score 
showed good calibration (calibration intercept = 0; slope = 1; Brier score 0.170) across the range of risk 
and no adjustment to the model was required (Appendix 11).
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Table 1. Demographic and clinical characteristics for derivation and validation cohorts for patients 
hospitalized with covid-19. 
Derivation
Derivation 
Total N (%)
Validation
Validation
Total N (%)
In-hospital mortality 11426 (32.2) 35463 (100.0) 6729 (30.1%) 22361 (100.0)
Age (years) <50 4876 (13.8) 35277 (99.5) 2808 (12.6) 22361 (100.0)
50-69 10183 (28.9) 5762 (25.8)
70-79 8017 (22.7) 4951 (22.1)
80+ 12201 (34.6) 8840 (39.5)
Sex at Birth Female 14741 (41.7) 35356 (99.7) 10178 (45.6) 22319 (99.8)
Ethnicity White 26300 (82.2) 31987 (90.2) 16831 (84.9) 19818 (88.6)
South Asian 1647 (5.1) 811 (4.1)
East Asian 271 (0.8) 140 (0.7)
Black 1256 (3.9) 769 (3.9)
Other Ethnic 
Minority
2513 (7.9) 1267 (6.4)
Chronic cardiac disease Yes 10513 (31.8) 33090 (93.3) 7019 (34.0) 20616 (92.2)
Chronic kidney disease Yes 5653 (17.2) 32834 (92.6) 3769 (18.4) 20444 (91.4)
Malignant neoplasm Yes 3312 (10.2) 32556 (91.8) 2187 (10.8) 20297 (90.8)
Moderate or severe liver disease Yes 604 (1.9) 32538 (91.8) 434 (2.1) 20218 (90.4)
Obesity (clinician defined) Yes 3414 (11.4) 29829 (84.1) 2234 (12.2) 18304 (81.9)
Chronic pulmonary disease
(not asthma)
Yes 5830 (17.7) 32990 (93.0) 3737 (18.2) 20502 (91.7)
Diabetes (type 1 & type2) Yes 8487 (26.0) 32622 (92.0) 4275 (21.9) 19511 (87.3)
Number of comorbidities 0 8497 (24.0) 35463 (100.0) 5098 (22.8) 22361 (100.0)
1 9941 (28.0) 6114 (27.3)
2+ 17025 (48.0) 11149 (49.9)
Respiratory Rate Median (IQR) 22.0 (9.0) 33330 (94.0) 20.0 (8.0) 20970 (93.8)
Oxygen saturation (%) Median (IQR) 94.0 (6.0) 33696 (95.0) 94.0 (5.0) 21197 (94.8)
Systolic blood pressure (mmHg) Median (IQR) 124.0 (33.0) 33637 (94.9) 129.0 (33.0) 21073 (94.2)
Diastolic blood pressure (mmHg) Median (IQR) 70.0 (19.0) 33568 (94.7) 73.0 (20.0) 21026 (94.0)
Temperature (°C) Median (IQR) 37.3 (1.5) 33467 (94.4) 37.1 (1.5) 21139 (94.5)
Heart Rate (bpm) Median (IQR) 90.0 (27.0) 33405 (94.2) 90.0 (28.0) 20991 (93.9)
Glasgow Coma Scale Median (IQR) 15.0 (0.0) 30819 (86.9) 15.0 (0.0) 20015 (89.5)
Haemoglobin (g/L) Median (IQR) 129.0 (30.0) 29924 (84.4) 127.0 (31.0) 18480 (82.6)
White blood cell count (109/L) Median (IQR) 7.4 (5.1) 29740 (83.9) 7.6 (5.3) 18362 (82.1)
Neutrophil count (109/L) Median (IQR) 5.6 (4.6) 29594 (83.5) 5.8 (4.9) 18354 (82.1)
Lymphocyte count (109/L) Median (IQR) 0.9 (0.7) 29553 (83.3) 0.9 (0.7) 18348 (82.1)
Platelet Count (109/L) Median (IQR) 216.0 (120.0) 29582 (83.4) 223.0 (126.0) 18281 (81.8)
Sodium (mmol/L) Median (IQR) 137.0 (6.0) 29522 (83.2) 137.0 (6.0) 18409 (82.3)
Potassium (mmol/L) Median (IQR) 4.1 (0.8) 27224 (76.8) 4.1 (0.8) 16926 (75.7)
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Derivation
Derivation 
Total N (%)
Validation
Validation
Total N (%)
Total Bilirubin (mg/dL) Median (IQR) 10.0 (7.0) 24446 (68.9) 10.0 (7.0) 15404 (68.9)
Urea Median (IQR) 7.0 (6.3) 26122 (73.7) 7.3 (6.8) 16863 (75.4)
Creatinine Median (IQR) 86.0 (53.0) 29439 (83.0) 86.0 (56.0) 18225 (81.5)
C-reactive protein Median (IQR) 84.9 (122.0) 27856 (78.5) 78.0 (120.0) 17119 (76.6)
Values stated as median with IQR in parentheses for continuous variables, patient number with percentage in 
parentheses for categorical variables. Comorbidities were defined using the Charlson Comorbidity Index, with the 
addition of clinician-defined obesity.
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Table 2. Final 4C Mortality Score for in-hospital mortality in patients with covid-19. Prognostic index 
derived from penalised logistic regression (LASSO) model. 
Variable 4C Mortality 
Score
<50
50-59 +2
60-69 +4
70-79 +6
Age (years)
≥80 +7
Female
Sex at birth
Male +1
0
1 +1Number of comorbidities*
≥2 +2
<20
20-29 +1Respiratory rate (breaths/minute)
≥30 +2
≥92
Peripheral oxygen saturation on room air (%)
<92 +2
15
Glasgow Coma Scale
<15 +2
≤7
7-14 +1Urea (mmol/L)
>14 +3
<50
50-99 +1CRP (mg/dL)
≥100 +2
*Comorbidities were defined using the Charlson Comorbidity Index, with the addition of clinician-defined obesity
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Table 3. Model discrimination in validation cohort. 
AUROC, area under receiver operator curve; CI, confidence interval. 
Derivation Validation
Model AUROC (95% CI) Brier score AUROC (95% CI) Brier score
4C Mortality Score 0.786 (0.781 – 0.790) 0.170 0.767 (0.760 – 0.773) 0.171
Machine learning comparison 
(gradient boosting decision tree 
[XGBoost])
0.796 (0.786 – 0.807) 0.191 0.779 (0.772 – 0.785) 0.197 
Page 15 of 59
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15
Figure 2. A, distribution of patients across range of 4C Mortality Score in validation cohort. B, observed inpatient mortality across range of 4C 
Mortality Score in derivation cohort. C, predicted versus observed probability of inpatient mortality (calibration; red line) with distribution of 
patients across predicted probability (vertical black lines) for 4C Mortality Score within derivation cohort.
Page 16 of 59
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16
Figure 3. Receiver operator characteristic (ROC) curves (A) and decision curve analysis (B) for most discriminating three models applicable to 
>50% of validation population, compared with age alone (restricted cubic spline) (imputed datasets). B, Lines are shown for standardised net
benefit at different risk thresholds of treating no patients (black) and treating all patients (grey).
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Model validation
The validation cohort included data from 22 361 patients collected between 21st May 2020 and 29th June 
2020 who had at least four weeks follow-up. 743 (3.3%) patients had no outcome recorded and were 
considered alive. The overall mortality was 28.6% (10 998 patients). The median age of patients in the 
cohort was 76 (interquartile range (IQR) 60-85) years. 10 178 (45.6%) were female and 17 263 (77%) of 
patients had at least one comorbidity (Table 1). 
Discrimination of the 4C Mortality Score in the validation cohort was similar to that of the XGBoost 
model (Table 3). Calibration was also found to be excellent in the validation cohort: overall observed 
(30.1%) vs predicted (30.1%) mortality was equal (calibration-in-the-large = 0) and calibration was 
excellent over the range of risk (slope = 1, Brier score 0.171) (Figure 2). The 4C Mortality Score 
demonstrated good performance in clinically relevant metrics, across a range of cut-offs (Table 4).
Four risk groups were defined with corresponding mortality rates determined (Table 5): low risk (0-3 
score; mortality rate 1.2%), intermediate risk (4-8 score; 9.9%), high risk (9-14 score; 31.4%), and very 
high risk (≥15 score; 61.5%). Performance metrics demonstrated a high sensitivity (99.7%) and negative 
predictive value (NPV; 98.8%) for the low-risk group, covering 7.4% of the cohort and a corresponding 
mortality rate of 1.2%. 
Patients in the intermediate risk group (score 4-8; n = 4889, 21.9%) had a mortality rate of 9.9% (NPV 
90.1%). 
High-risk patients (score 9-14; n = 11 664, 52.2%) had a 31.4% mortality (NPV 68.6), while patients 
scoring ≥15 (n = 4158, 18.6%) had a 61.5% mortality (positive predictive value 61.5%).
Comparison with existing tools
A total of 15 risk stratification scores that could be applied to these data were identified through a 
systematic literature search.6,22,28–40 The 4C Mortality Score compared well against these existing risk 
stratification scores in predicting inpatient mortality (Table 6, Figure 3A). Risk stratification scores 
originally validated in patients with community-acquired pneumonia (N = 9) generally had higher 
discrimination for inpatient mortality in the validation cohort (e.g., A-DROP [AUROC 0.74; 95% CI 0.73 – 
0.75], E-CURB65 [0.76; 0.74 – 0.79]) than those developed within covid-19 cohorts (n = 4: Surgisphere 
[0.63; 0.62 – 0.64], DL score [0.67; 0.66 – 0.68], COVID-GRAM [0.71; 0.68 – 0.74] and Xie score [0.73; 
0.71 – 0.76]). Performance metrics for the 4C Mortality Score compared well against existing risk 
stratification scores at specified cut-offs (Appendix 13).
The number of patients in whom risk stratification scores could be applied differed due to certain 
variables not being available, either due to missingness or because they were not tested for/recorded in 
clinical practice. Seven scores could be applied to fewer than 2000 patients (<10%) in the validation 
cohort, due to the requirement for biomarkers or physiological parameters that were not routinely 
captured (e.g. lactate dehydrogenase [LDH]).
Decision curve analysis demonstrated that the 4C Mortality Score had better clinical utility across a wide 
range of threshold risks compared with the best performing existing scores applicable to >50% of the 
validation cohort (A-DROP and CURB65) (Figure 3B).  
18
Table 4. Performance metrics of 4C Mortality Score to rule-out mortality (A) and rule-in mortality (B) at 
different cut-offs in validation cohort.
A
Number of patients 
at cut-off (%) TP TN FP FN Sensitivity Specificity PPV NPV
Mortality
(%)
<=2 1001 (4.5) 6724 996 14636 5 99.9 6.4 31.5 99.5 0.5
<=3 1650 (7.4) 6709 1630 14002 20 99.7 10.4 32.4 98.8 1.2
<=4 2420 (10.8) 6672 2363 13269 57 99.2 15.1 33.5 97.6 2.4
<=6 4121 (18.4) 6542 3934 11698 187 97.2 25.2 35.9 95.5 4.5
<=8 6539 (29.2) 6223 6033 9599 506 92.5 38.6 39.3 92.3 7.7
<=9 8167 (36.5) 5911 7349 8283 818 87.8 47 41.6 90.0 10.0
B
Number of 
patients at cut-
off (%)
TP TN FP FN Sensitivity Specificity PPV NPV Mortality (%)
>=9 15822 (70.8) 6223 6033 9599 506 92.5 38.6 39.3 92.3 39.3
>=11 12325 (55.1) 5483 8790 6842 1246 81.5 56.2 44.5 87.6 44.5
>=13 8069 (36.1) 4206 11769 3863 2523 62.5 75.3 52.1 82.3 52.1
>=15 4158 (18.6) 2557 14031 1601 4172 38 89.8 61.5 77.1 61.5
>=17 1579 (7.1) 1142 15195 437 5587 17 97.2 72.3 73.1 72.3
>=19 381 (1.7) 305 15556 76 6424 4.5 99.5 80.1 70.8 80.1
TP, true positive; TN, true negative; FP, false positive; FP, false positive; PPV, positive predictive value; NPV, 
negative predictive value. 
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Table 5. Comparison of mortality rates for 4C Mortality Score risk groups across derivation and 
validation cohorts.
Derivation cohort    Validation cohort
Risk group Number of 
patients (%)
Mortality 
(%)
Number of 
patients (%)
Mortality 
(%)
Low (0-3) 2574 (7.3)) 45 (1.7) 1650 (7.4) 20 (1.2)
Intermediate (4-8) 8277 (23.3) 751 (9.1) 4889 (21.9) 486 (9.9)
High (9-14) 18091 (51.0) 6310 (34.9) 11 664 (52.2) 3666 (31.4)
Very high (≥15) 6521 (18.4) 4320 (66.2) 4158 (18.6) 2557 (61.5)
Overall 35 463 11 426 22 361 6729
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Table 6. Discriminatory performance of risk stratification scores within validation cohort (complete case) 
to predict inpatient mortality in patients hospitalised with covid-19. See appendix 13 for other metrics. 
Validation cohort (available data)
Number of patients with 
required parameters AUROC (95% CI)
SOFA 197 0.614 (0.530-0.698)
qSOFA 19361 0.622 (0.615-0.630)
Surgisphere* 18986 0.630 (0.622-0.639)
SMARTCOP 486 0.645 (0.593-0.697)
NEWS 19074 0.654 (0.645-0.662)
DL score* 16345 0.669 (0.660-0.678)
SCAP 370 0.675 (0.620-0.729)
CRB65 19361 0.683 (0.676-0.691)
COVID-GRAM* 1239 0.706 (0.675-0.736)
DS-CRB65 18718 0.718 (0.710-0.725)
CURB65 15560 0.720 (0.713-0.728)
Xie score* 1753 0.727 (0.701-0.753)
A-DROP 15572 0.736 (0.728-0.744)
PSI 360 0.736 (0.683-0.790)
E-CURB65 1553 0.764 (0.740-0.788)
4C Mortality Score 14398 0.774 (0.767-0.782)
*novel covid-19 risk stratification score
Sensitivity analysis
Sensitivity analyses using complete case data showed similar discrimination (appendix 7) and 
performance metrics (appendix 8 and appendix 9) to analyses using the imputed datasets. 
After stratification of the validation cohort into two geographical cohorts (validation north and south; 
Appendix 14), discrimination remained similar for the 4C Mortality Score in both the North (AUROC 0.78, 
95% CI 0.77 – 0.79) and South (0.77, 0.56 – 0.78) subsets (Appendix 6).
Finally, discrimination of the 4C Mortality Score by sex and in ethnic groups was checked. Discrimination 
was the same in males (AUROC 0.768, 0.759 – 0.776) and females (AUROC 0.764, 0.754 – 0.773). 
Discrimination was better in all non-White ethnic groups compared to the White group: South Asian 
(AUROC 0.823, 0.795 – 0.851), East Asian (AUROC 0.851, 0.790 – 0.912), Black (AUROC 0.827, 0.796 –
0.857) and Other ethnic minority (AUROC 0.813, 0.789 – 0.838). 
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Discussion
Principal findings
We have developed and validated the eight-variable 4C Mortality Score for in-patient death in a UK 
prospective cohort of 57 824 patients hospitalised with covid-19. The 4C Mortality Score uses patient 
demographics, clinical observations, and blood parameters that are commonly available at the time of 
hospital admission and can accurately characterise the population of patients at a high risk of in-hospital 
death. It compared favourably to other models, including ‘best-in-class’ machine learning techniques 
and demonstrated consistent performance across the validation cohorts including good clinical utility in 
a decision curve analysis.
Model performance compared well against other generated models, with minimal loss in discrimination 
despite its pragmatic nature. A machine learning approach demonstrated a marginal improvement in 
discrimination, but at the cost of interpretability, the requirement for many more input variables, and 
the need for an app/website calculator which may limit use at the bedside given PPE requirements. The 
4C Mortality Score demonstrated good applicability within the validation cohort and consistency across 
all performance measures. 
Comparison with other studies
The 4C Mortality Score contains parameters reflecting patient demographics, comorbidity, physiology, 
and inflammation at hospital admission. It shares characteristics with existing prognostic scores for 
sepsis and community-acquired pneumonia but has important differences as well. To our knowledge, no 
pre-existing score uses this combination of variables and weightings. Altered consciousness and high 
respiratory rate are included in most risk stratification scores for sepsis and community-acquired 
pneumonia,21,22,28,29,32,33,36 while elevated urea is also a common component.21,22,28 Increasing age is a 
strong predictor of inpatient mortality within our hospitalised covid-19 cohort and is commonly included 
in other existing covid-19 scores,37,41,42 together with comorbidity37,41,42 and elevated CRP.40,43
Discriminatory performance of existing covid-19 scores applied to our cohort was lower than reported in 
derivation cohorts (DL score 0.74; COVID-GRAM 0.88; Xie score 0.98).37,38,40 The use of small inpatient 
cohorts from Wuhan, China, for model development may have resulted in over-fitting, limiting 
generalisability in other cohorts.38,40 The Xie score demonstrated the highest discriminatory power 
(0.73), and included age, lymphocyte count, LDH, and peripheral oxygen saturations. However, we were 
only able to apply this score for <10% of the validation cohort as LDH is not routinely measured on 
hospital admission in the UK. 
Due to challenges of clinical data collection during an epidemic, missing data is common, with choice of 
predictors influenced by data availability.40 Complete case analysis often leads to exclusion of a 
substantial proportion of the original sample, subsequently leading to a loss of precision and power.44 
However, the assessment of missing data on model performance in novel covid-19 risk stratification 
scores has been limited37 or unexplored38,40, potentially introducing bias and further limiting 
generalisability to other cohorts. We found discriminatory performance in both derivation and 
validation cohorts remained similar after the imputation of a wide range of variables (41), further 
supporting the validity of our findings.
22
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The presence of comorbidities is handled differently in covid-19 prognostic scores, either included 
individually,40,42 given equal weight,37 or found to have no predictive effect.38 Recent evidence suggests 
an additive effect of comorbidity in covid-19 patients, with increasing number of comorbidities 
associated with poorer outcomes.16 In our cohort, the inclusion of individual comorbidities within the 
machine learning model conferred minimal additional discriminatory performance, supporting the 
inclusion of an overall comorbidity count.
Strengths and limitations of this study
The ISARIC WHO CCP-UK study represents the largest prospectively collected covid-19 hospitalised 
patient cohort in the world and reflects the clinical data available in most economically developed 
healthcare settings. We derived a clinically applicable prediction score with clear methodology and 
tested it against existing risk stratification scores in a large hospitalised patient cohort. It compared 
favourably to other prognostic tools, with good to excellent discrimination, calibration, and performance 
characteristics.
The 4C Mortality Score has several methodological advantages over current covid-19 prognostic scores. 
The use of penalised regression methods and an event-to-variable ratio greater than 100 reduce the risk 
of over-fitting.45,46 The use of parameters commonly available at first assessment increases its clinical 
applicability, avoiding the requirement for markers often only available after a patient has been 
admitted to a critical care facility.4,47 It is of course a fait accompli that a model developed in a specific 
dataset should describe that dataset best. However, including comparisons with pre-existing models 
provides reassurance that equivalent performance cannot be delivered with a simple tool already in use.    
In addition, in a pandemic, baseline infection rates and patient characteristics may change by time and 
geography. This motivated the temporal and geographical validation which is crucial to the reporting of 
this study. These sensitivity analyses demonstrated that score performance was continued to be robust 
over time and geography. 
Our study has limitations. First, we were unable to evaluate the predictive performance of a number of 
existing scores that require a large number of parameters (for example APACHE II48), as well as several 
other covid-19 prognostic scores that use computed tomography findings or uncommonly measured 
biomarkers.5 In addition, several potentially relevant comorbidities, such as hypertension, previous 
myocardial infarction and stroke16 were not included in data collection. Their inclusion might have 
impacted upon or improved 4C Mortality Score performance and generalisability. 
Second, a proportion of recruited patients (3.3%) had incomplete episodes. Selection bias is possible if 
patients with incomplete episodes, such as those with prolonged hospital admission, had a differential 
mortality risk to those with completed episodes. Nevertheless, the size of our patient cohort compares 
favourably to other datasets for model creation. The patient cohort on which the 4C Mortality Score was 
derived comprised hospitalised patients who were seriously ill (mortality rate of 32.2%) and were of 
advanced age (median age 74 years). This model is not for use in the community and may perform 
differently in populations at lower risk of death. Further external validation is required to determine 
whether the 4C Mortality Score is generalisable among younger patients and in settings outside the UK. 
23
Conclusions and policy implications
We have derived and validated an easy-to-use eight-variable risk stratification score that enables 
accurate stratification of hospitalised covid-19 patients by mortality risk at hospital presentation. 
Application within the validation cohorts demonstrated this tool may guide clinician decisions, including 
treatment escalation. 
A key aim of risk stratification is to support clinical management decisions. Four risk classes were 
identified and demonstrated similar adverse outcome rates across the validation cohort. Patients with a 
4C Mortality Score falling within the low-risk groups (mortality rate 1%) might be suitable for 
management in the community, while those within the intermediate-risk group were at lower risk of 
mortality (mortality rate 10%; 22% of the cohort) and may be suitable for ward-level monitoring. Similar 
mortality rates have been identified as an appropriate cut-off in pneumonia risk stratification scores 
(CURB-65 and PSI).21,22 Meanwhile patients with a score ≥9 were at high risk of death (~40%), which may 
prompt aggressive treatment, including the commencement of steroids,49 and early escalation to critical 
care if appropriate. 
List of figures
Figure 1. Model derivation and validation workflow.
Figure 2. A, distribution of patients across range of 4C Mortality Score in validation cohort. B, observed 
inpatient mortality across range of 4C Mortality Score in derivation cohort. C, predicted versus observed 
probability of inpatient mortality (calibration; red line) with distribution of patients across predicted 
probability (vertical black lines) for 4C Mortality Score within derivation cohort.
Figure 3. Receiver operator characteristic (ROC) curves (A) and decision curve analysis (B) for most 
discriminating three models applicable to >50% of validation population, compared with age alone 
(restricted cubic spline) (imputed datasets). B, Lines are shown for standardised net benefit at different 
risk thresholds of treating no patients (black) and treating all patients (grey). 
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End matter
What is already known on this topic
 There is a lack of robust, validated clinical prediction tools to identify patients with covid-19 who
are at the highest risk of mortality
 Given uncertainty about how to stratify covid-19 patients, there is considerable interest in risk
stratification scores to support frontline clinical decision making
 Available risk stratification tools however suffer from a high risk of bias, small sample size
resulting in uncertainty, poor reporting and lack of formal validation
What this study adds
 The majority of existing covid-19 risk stratification tools performed poorly in our cohort –
caution should be applied when using novel tools based on small patient populations to in-
hospital cohorts with covid-19
 In contrast, our 4C (Coronavirus Clinical Characterisation Consortium) score is an easy-to-use
and valid prediction tool for inpatient mortality, accurately categorising patients as being at low,
intermediate, high, or very high-risk of death
 This pragmatic and clinically applicable score outperformed other risk stratification tools,
demonstrated clinical decision-making utility, and had similar performance to more complex
models
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Datasets
Primary model 
fitting
Prognostic index 
derivation and 
calibration
Validation and 
sensitivity 
analyses
ISARIC CCP-UK
All available data to 
20th May 2020
Generalised 
additive model 
(GAM)
Variables N = 21
Candidate 
predictor variables 
identified from 
literature and 
dataset
Variables N = 41
Variables excluded if high 
levels missingness (>33%)
Variables N = 13
Comorbidity variables 
combined
Variables N = 7
Cut-point selection
Penalised logistic 
regression 
(LASSO)
Calibration
Primary validation
Comparison with 
existing scores
- Continuous variables with 
thin-plate splines;
- Parametric categorical variables;
- Criterion-based model selection:
- deviance explained.
- Component smoothed 
functions on scale of 
linear predictor from 
GAM model used.
Variables not contributing 
to model fit excluded
Variables N = 13
- Prognostic index 
derivation using 
L1-penalised regression 
coefficients.
- Predicted vs observed 
mortality across deciles 
of risk.
Machine learning 
model comparison
(XGBoost)
Variables N = 28
- Gradient boosting 
decision tree;
- Random 80/20% 
training/test split;
- Trained on binary 
classification error;
- Missing data modelled. 
All variables retained
- 15 pre-existing scores 
derived in COVID-19 
and non-COVID-19 
settings.
Derivation dataset
ISARIC CCP-UK
All available data to 
20th ay 2020
N = 35 463
Validation dataset
ISARIC CCP-UK
data collected 
subsequent to 
primary analysis
N = 22 361
Validation 
"North" subset
N = 13 769
Validation 
"South" subset 
N = 8 592
Secondary 
validation
- Sensitivity
- Specficity
- PPV
- NPV
- AUROC
- Brier score
- Calibration
Creation of geographical 
cohorts using 'North-South' 
divide for sensitivity analysis
Multiple imputation
- Multvariable imputation by chained equations;
- 28 predictor variables;
- 10 iterations, 10 imputed sets;
- Distributions inspected & convergence 
confirmed.
Multiple imputation
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1Supplementary material
Appendix 1. ISARIC WHO CCP-UK risk stratification score derivation and validation protocol
Background
Patients hospitalised with covid-19 are at high risk of mortality. Stratification of patients on admission may aid 
clinicians in determining immediate management decisions (home discharge, ward-level care, escalation to ICU) and 
medical treatment. High risk of bias exists in novel covid-19 risk stratification tools, with small cohorts in limited 
geographical areas and potential for over-fitting. Many of these scores are also complex to calculate. This limits 
clinical utility.
Aims
 Develop risk stratification score using the largest known hospitalised cohort of covid-19 patients
 The risk stratification score must have high clinical utility (defined here as having the ability to be calculated
without a complex equation or algorithm)
 Following derivation, determine discriminatory performance in validation cohorts and compare to existing
risk stratification tools (for pneumonia, influenza and covid-19)
Primary outcome
In-hospital mortality with minimum 28d follow up.
Patient inclusion
 All adult patients (≥18 years old on admission)
 Index admission (readmission episode excluded)
 Completed index admission
Potential candidate variables
Identification
The systematic literature search (see below) will identify potential predictor variables for mortality, disease severity 
and/or critical care requirement in pneumonia, influenza or covid-19 patients.
Inclusion criteria
 Readily available patient or clinical characteristic to attending clinicians upon presentation to hospital
(Accident & Emergency department, Acute Medical Receiving Unit)
 Blood markers should be commonly measured and results available for review within the first 24 hours of
admission
 Measured within the ISARIC WHO CCP-UK database (pre-specified case report form)
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2Exclusion criteria
 Variable with missing values in >33% of patients within the derivation cohort
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Score development
All patients within the database on 20th May 2020 will be included within the derivation cohort.
With the overall aim to derive a risk stratification score with high clinical utility, an a priori decision has been made to 
categorise final included predictor variables for ease of calculation in a clinical environment. However, to avoid loss of 
information through categorisation, generalised additive models (GAMs) will be used first to identify final predictor 
variables prior to categorisation.
All remaining candidate predictor variables following application of exclusion criteria (availability in database, 
missingness) will be entered into a GAMs. These variables will then be removed individually and GAMs run again, 
determining the explained deviance and unbiased risk estimator (UBRE; essentially a scaled AIC) following exclusion 
of each individual variable. Final variables to include within the risk stratification score will then be selected by 
explained deviance, R2 and UBRE.
GAMs curves for each continuous variable will then be created for each final included variable and cut-offs 
determined based on outcome risk. Once categorised, the final variables will be placed in a least absolute shrinkage 
and selection operator (LASSO) to ensure all final variables should be selected within the risk score and to reduce 
the risk of over-fitting. Shrunk coefficients will be converted to produce an index score.
In parallel, a machine learning (ML) model will be derived using extreme gradient boosted trees methodology 
(XGBoost), representing a ‘best-in-class’ model. This will include all candidate predictor variables included within the 
GAM model.
Statistical analysis
Model performance will be determined using the AUROC, with calibration and Brier score calculated for each final 
model (derived risk score and ML model). 
To determine the impact of missingness, a missing data analysis will be performed. Multivariate imputation by 
chained equations (MICE) will be used for all candidate predictor variables (except those with high levels of 
missingness). It will be assumed that variables are missing at random and the primary outcome will be used in 
derivation dataset imputation models. Ten sets with ten iterations will be performed. Model performance will again be 
determined as detailed above, with Rubin’s Rules used to combine model parameter estimates.
All statistical analysis will use the R (v3.6.3).
Validation
All patients entered into the database after the specified derivation cohort cut-off will be included, with the same 
patient inclusion/criteria applied.
Exiting risk stratification tool identification
Risk stratification scores created and or validated for pneumonia, influenza and covid-19 will be included. These will 
be identified through the systematic literature search (see below) and do not have to have been peer-reviewed for 
inclusion.
Only risk stratification scores with all predictor variables will be considered for inclusion. Decisions for inclusion of risk 
stratification score where one variable is missing will be made on a case-by-case basis by consensus within the study 
group. If the missing variable is deemed a key contributor to risk prediction within the tool it will be excluded. 
3Statistical analysis
Discriminatory performance (AUROC) and other performance metrics (sensitivity, specificity, PPV and NPV) will be 
calculated for all included risk stratification tools and compared with the derived risk and ML model in each of the 
validation cohorts. Calibration and Brier score will also be determined for the derived risk score in each validation 
cohort.
Systematic literature search
Databases
EMBASE, WHO Medicus and Google Scholar (particularly for pre-print publications)
Search terms
Pneumonia; sepsis; influenza; covid-19; SARS-CoV-2; coronavirus; 
Combined with: score and prognosis 
No language or date restrictions
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4Appendix 2. Candidate predictor variables evaluated for potential inclusion in modelling process
Evidence and/or models Inclusion / exclusion
Patient demographics
Age on admission (years) CURB-65a, COVID-GRAMb Included
Sex at Birth A-DROPc, PSId Included
Ethnicity Ethnicity predicts clinical outcomes in covid-19e Included
Hypertension Comorbidity predicts clinical outcomes in covid-19f
Excluded – not initially recorded 
within the ISARIC CCP-UK database
Chronic cardiac disease Comorbidity predicts clinical outcomes in covid-19f
Combined with other comorbidities 
for model development
Chronic kidney disease Comorbidity predicts clinical outcomes in covid-19f
Combined with other comorbidities 
for model development
Malignant neoplasm Comorbidity predicts clinical outcomes in covid-19f
Combined with other comorbidities 
for model development
Moderate or severe liver 
disease
Comorbidity predicts clinical outcomes in covid-19f
Combined with other comorbidities 
for model development
Obesity (clinician defined) Comorbidity predicts clinical outcomes in covid-19f
Combined with other comorbidities 
for model development
Chronic pulmonary disease
(not asthma)
Comorbidity predicts clinical outcomes in covid-19f
Combined with other comorbidities 
for model development
Diabetes (type 1 & type 2) Comorbidity predicts clinical outcomes in covid-19 f
Combined with other comorbidities 
for model development
Number of comorbidities
Number of comorbidities predicts clinical outcomes in 
covid-19f
Included – composite count of all 
included comorbidities defined by 
Charlson Comorbidity Index plus 
obesity
Clinical signs/ observations
Respiratory Rate CURB65a, NEWS2g Included
Peripheral oxygen saturations 
(%)
Xie scoreh, ADROPc Included
Systolic blood pressure (mmHg) CURB-65a, NEWS2g Included
Diastolic blood pressure 
(mmHg)
CURB-65a Included
Temperature (°C) PSId, NEWS2g Included
Heart Rate (bpm) NEWS2g Included
Glasgow Coma Score COVID-GRAMb, CURB-65a Included
Bedside investigations
FiO2 NEWS2g, SOFAi
Excluded – too many values missing 
from derivation dataset
PaO2 (kPa) PSId, SCAPj
Excluded – too many values missing 
from derivation dataset
pH PSId, SCAPj
Excluded – too many values missing 
from derivation dataset
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5Evidence and/or models Inclusion / exclusion
Glucose (mmol/L) PSId
Excluded – too many values missing 
from derivation dataset
Infiltrates on chest radiograph COVID-GRAMb , PSId, SMART-COPk
Excluded – too many values missing 
from derivation dataset
Laboratory measures
Haemoglobin (g/L)
Severe covid-19 known to lower haemoglobin 
concentrationl
Included
White cell count (109/L) COVID-GRAMb Included
Neutrophil count (109/L) COVID-GRAMb, DL scorem Included
Lymphocyte count (109/L) COVID-GRAMb Included
Haematocrit (%) PSId
Excluded – too many values missing 
from derivation dataset
Platelet Count (109/L) DL scorem, E-CURB65n Included
Prothrombin (seconds)
Coagulopathy associated with mortality in covid-19 
patientso
Excluded – too many values missing 
from derivation dataset
Activated partial 
thromboplastin time (APTT) 
(seconds)
Coagulopathy associated with mortality in covid-19 
patientso
Excluded – too many values missing 
from derivation dataset
Sodium (mmol/L) PSId Included
Total Bilirubin (mg/dL) COVID-GRAMb, SOFAi Included
Alanine aminotransferase (ALT) 
(units/L)
Abnormal liver tests associated with severe covid-19p
Excluded – too many values missing 
from derivation dataset
Aspartate aminotransferase 
(AST) (units/L)
Abnormal liver tests associated with severe covid-19p
Excluded – too many values missing 
from derivation dataset
Albumin (g/L) Association between low albumin and severe covid-19q
Excluded - not recorded within ISARIC 
CCP-UK database
Lactate dehydrogenase 
(Units/L)
COVID-GRAMb, E-CURB65n
Excluded – too many values missing 
from derivation dataset
Urea (mmol/L) CURB-65a, A-DROPc, PSId Included
Creatinine (µmol/L) SOFAi Included
C-reactive protein (CRP; mg/dL)
Associated with poorer outcomes in patients with covid-
19r, s
Included
aCURB65 (abbreviation representing included model variables)
bCOVID-GRAM (Liang JAMA Int Med 2020)
cA-DROP (abbreviation representing included model variables)
dPneumonia Severity Index (PSI)
ePan 2020. EClin Med; doi: https://doi.org/10/1016/j.eclinm.2020.100404 
fGuan 2020. Eur Respir J. May; 55(5): 2000547
gNational Early Warning Score (NEWS2)
hXie score (Xie MedRxiv 2020)
iSequential Organ Failure Assessment (SOFA) score
jSevere Community Acquired Pneumonia (SCAP) score
kSMART-COP (abbreviation representing included model variables)
lLippi G et al. Hematol Transfus Cell Ther. 2020
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6mDL score (Zhang MedRxiv 2020)
nExpanded CURB65 score (E-CURB65)
oZhou 2020, Lancet 395; P1054-1062
pCai 2020, DOI: https://doi.org/10.1016/j.jhep.2020.04.006
qAziz 2020, Critical Care. 24:255
rLiu 2020, European Respiratory Journal; 55(5): 2001112
sLuo 2020, Clin Infect Dis; doi: https//doi.org/10.1093/cid/ciaa641
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7Appendix 3. Criterion-based approach using generalised additive models for remaining 20 candidate 
variables following exclusion for missing values. Inclusion criteria specified as >1% change in deviance 
explained (>0.2) or >10% change in the unbiased risk estimator (>0.002) compared to the full GAM 
model containing all candidate variables.
Variable
Deviance 
explained 
(%) 
Reduction in 
deviance 
explained on 
removal from 
21 variable 
model (%) 
R2
Unbiased 
Risk 
Estimator 
(UBRE)
Area 
under 
receiver 
operator 
cure
Included 
in final 
model
All candidate variables 23.3 - 0.261 -0.030 0.811 -
Age 19.1 4.2 0.221 0.022 0.786 Included
Sex at Birth 23.1 0.2 0.260 -0.029 0.811 Included
Ethnicity 23.2 0.1 0.261 -0.030 0.811
Number of comorbidities 22.9 0.4 0.258 -0.026 0.809 Included
Respiratory Rate 22.8 0.5 0.256 -0.025 0.809 Included
Peripheral oxygen saturations 22.2 1.1 0.249 -0.017 0.805 Included
Systolic blood pressure 23.2 0.0 0.261 -0.030 0.811
Diastolic blood pressure 23.2 0.0 0.261 -0.030 0.811
Temperature 23.2 0.0 0.261 -0.030 0.811
Heart Rate 23.1 0.1 0.260 -0.029 0.810
Glasgow Coma Score 22.9 0.4 0.257 -0.025 0.809 Included
Haemoglobin 23.1 0.1 0.260 -0.029 0.810
White cell count 23.2 0.0 0.261 -0.030 0.811
Neutrophil count 23.2 0.0 0.261 -0.030 0.811
Lymphocyte count 23.1 0.1 0.260 -0.029 0.809
Platelet Count 23.1 0.1 0.260 -0.029 0.810
Sodium 23.2 0.0 0.261 -0.030 0.811
Total Bilirubin 23.2 0.0 0.261 -0.030 0.811
Urea 22.7 0.6 0.256 -0.024 0.808 Included
Creatinine 23.2 0.0 0.261 -0.030 0.811
C-reactive protein 22.7 0.6 0.256 -0.024 0.808 Included
Final eight variable model 21.2 2.1 0.241 -0.009 0.798 -
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8Appendix 4. Continuous smoothed predictors (thin-plate splines) for numerical variables generated from 
primary generalised additive model (GAM). Linearity of response was assessed (log-odds scale) and the 
location of gradient changes determined. The methods of Barrio et al15 were used to identify cut points 
on the basis of slopes and the clinical significance of the cut point in question.
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9Appendix 5. A, penalised regression coefficients from LASSO logistic regression (log-odds scale) which 
were scaled to produce the prognostic index. B, regression coefficients (y-axis) at different values of L1 
penalty (x-axis) for 4C Mortality Score.
A
*Comorbidities were defined using the Charlson Comorbidity Index, with the addition of clinician-defined obesity
Level Penalised coefficient
Penalised coefficient 
(x3 scaling)
Intercept - -4.203 -13
50-59 0.687 2
60-69 1.337 4
70-79 1.842 6
Age (years)
≥80 2.252 7
  Sex at birth Male 0.172 1
1 0.300 1
  Number of comorbidities*
≥2 0.532 2
20-29 0.232 1
Respiratory rate (breaths/minute)
≥30 0.649 2
  Oxygen saturation on room air (%) <92 0.577 2
  Glasgow Coma Scale <15 0.558 2
7-14 0.439 1
Urea (mmol/L)
>14 1.011 3
50-99 0.363 1
CRP (mg/dL)
≥100 0.74 2
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11
Appendix 6. Discrimination of models in imputed validation dataset. Missing data patterns were 
analysed (finalfit package) and data were considered missing at random (as opposed to missing 
completely at random). Multiple imputation of missing values was performed (mice package) with 10 
iterations to create 10 imputed sets using the 28 predictor variables plus outcome for the derivation 
cohort, and 28 predictors without outcome in the validation cohort. Imputation methods were 
continuous variables: predictive mean matching; 2-level factors: binary logistic regression; and >2-level 
factors: polytomous regression (all considered unordered). Distributions of imputed variables were 
inspected across iterations. 
Generalised additive model (GAM) included continuous predictors with L2-penalised thin-plate splines 
with comorbidities considered as a continuous count. 
Gradient boosting tree (XGBoost) models included all continuous predictors and categorical predictors, 
including individual comorbidities. Two models were trained. The first used the multiply imputed 
datasets. The second used non-imputed data with missing modelled in the model building process. 
Penalised logistic regression (LASSO) model used categorised variables with discrimination determined 
using exact coefficients.   
4C mortality score is the prognostic index developed from the model building process. 
Variable 
N
Derivation
AUROC (95% CI)
Validation
AUROC (95% CI)
Validation North
AUROC (95% CI)
Validation South
AUROC (95% CI)
GAM 21 0.798 (0.793 – 0.803) 0.774 (0.767 – 0.780) 0.781 (0.773 – 0.789) 0.763 (0.752 – 0.774)
XGBoost (imputed) 28 0.796 (0.786 – 0.807) 0.779 (0.772 – 0.785) 0.785 (0.777 – 0.793) 0.769 (0.758 – 0.779)
XGBoost (missing 
modelled)
28 0.786 (0.775 – 0.797) 0.782 (0.776 – 0.788) 0.789 (0.781 – 0.797) 0.774 (0.763 – 0.785)
LASSO 8 0.788 (0.783 – 0.793) 0.768 (0.761 – 0.774) 0.772 (0.764 – 0.781) 0.761 (0.750 – 0.771)
4C mortality 8 0.786 (0.781 – 0.790) 0.767 (0.760 – 0.773) 0.771 (0.763 – 0.779) 0.760 (0.749 – 0.770)
GAM, generalized additive model; XGBoost, gradient boosting decision tree; LASSO, penalised logistic 
regression; AUROC, area under receiver operator characteristic curve; CI, confidence interval.  
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Appendix 7. Sensitivity analysis: discrimination of models with complete case data.
Variable N Derivation complete Validation complete
GAM 21 0.800 (0.794 – 0.806) 0.783 (0.776 – 0.791)
XGBoost (imputed) 28 0.772 (0.761 – 0.783) 0.782 (0.776 – 0.789) 
LASSO 8 0.789 (0.783 –0.795) 0.776 (0.769 – 0.784)
4C mortality 8 0.786 (0.780 – 0.792) 0.774 (0.767 – 0.782)
GAM, generalized additive model; XGBoost, gradient boosting decision tree; LASSO, penalised logistic regression; 
AUROC, area under receiver operator characteristic curve; CI, confidence interval.  
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Appendix 8. Sensitivity analysis with complete case data: Performance metrics of 4C Mortality Score to 
rule-out mortality (A) and rule-in mortality (B) at different cut-offs in validation cohort.
A
Number of patients 
at cut-off (%) TP TN FP FN Sensitivity Specificity PPV NPV
Mortality
(%)
<=2 539 (3.7) 4588 537 9271 2 100.0 5.5 33.1 99.6 0.4
<=3 955 (6.6) 4583 948 8860 7 99.8 9.7 34.1 99.3 0.7
<=4 1428 (9.9) 4558 1396 8412 32 99.3 14.2 35.1 97.8 2.2
<=6 2532 (17.6) 4478 2420 7388 112 97.6 24.7 37.7 95.6 4.4
<=8 4044 (28.1) 4296 3750 6058 294 93.6 38.2 41.5 92.7 7.3
<=9 5003 (34.7) 4115 4528 5280 475 89.7 46.2 43.8 90.5 9.5
B
Number of patients 
at cut-off (%) TP TN FP FN Sens Spec PPV NPV
Mortality 
(%)
>=9 10354 (71.9) 4296 3750 6058 294 93.6 38.2 41.5 92.7 41.5
>=11 8244 (57.3) 3835 5399 4409 755 83.6 55 46.5 87.7 46.5
>=13 5590 (38.8) 3012 7230 2578 1578 65.6 73.7 53.9 82.1 53.9
>=15 3019 (21.0) 1913 8702 1106 2677 41.7 88.7 63.4 76.5 63.4
>=17 1185 (8.2) 868 9491 317 3722 18.9 96.8 73.2 71.8 73.2
>=19 277 (1.9) 221 9752 56 4369 4.8 99.4 79.8 69.1 79.8
TP, true positive; TN, true negative; FP, false positive; FP, false positive; PPV, positive predictive value; NPV, 
negative predictive value. 
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Appendix 9. Sensitivity analysis with complete case data: Comparison of mortality rates for 4C Mortality 
Score risk groups across derivation and validation cohorts.
Derivation cohort    Validation cohort
Risk group Number of 
patients (%)
Mortality 
(%)
Number of 
patients (%)
Mortality 
(%)
Low (0-3) 1472 (6.9) 22 (1.5) 955 (6.6) 7 (0.7)
Intermediate (4-8) 4873 (22.7) 429 (8.8) 3089 (21.5) 287 (9.3)
High (9-14) 10 795 (50.3) 3779 (35.0) 7335 (50.9) 2383 (32.5)
Very high (≥15) 4305 (20.1) 2816 (65.4) 3019 (21.0) 1913 (63.4)
Overall 21 445 7046 14 142 4590
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Appendix 10. Sensitivity analysis with imputed datasets: Discrimination of 4C Mortality Score by 
ethnicity and sex. 
N DerivationAUROC (95% CI) N
Validation 
AUROC (95% CI)
Sex at birth Male 20678 0.785 (0.779-0.791) 12164 0.768 (0.759-0.776)
Female 14785 0.786 (0.778-0.793) 10197 0.764 (0.754-0.773)
Ethnicity White 29030 0.778 (0.773-0.783) 18924 0.757 (0.750-0.764)
South Asian 1868 0.823 (0.803-0.843) 951 0.823 (0.795-0.851)
East Asian 303 0.808 (0.757-0.859) 175 0.851 (0.790-0.912)
Black 1443 0.817 (0.793-0.840) 871 0.827 (0.796-0.857)
Other Ethnic Minority 2819 0.803 (0.785-0.820) 1440 0.813 (0.789-0.838)
AUROC, area under receiver operator characteristic curve; N, number of patients; CI, confidence interval. 
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Appendix 11. Calibration plot of 4C Mortality Score in derivation cohort.
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Appendix 12. Components of included risk stratification scores (*indicates novel covid-19 risk score).
A
B
Score Condition Outcome
A-DROP (Miyashita Int Med 2006) Community-acquired pneumonia 30-day mortality
COVID-GRAM (Liang JAMA Int Med 2020) covid-19 Mortality and/or ICU admission
CRB65 (Bauer J Int Med 2006) Community-acquired pneumonia 30-day mortality
CURB65 (Lim Thorax 2003) Community-acquired pneumonia 30-day mortality
DL score (Zhang MedRxiv 2020) covid-19 Mortality / ICU admission
DS-CRB65 (Dwyer BMJ ORR 2014) Community-acquired pneumonia 30-day mortality
E-CURB65 (Liu Sci Rep 2016) Community-acquired pneumonia 30-day mortality
NEWS2 (Royal College of Physicians, UK 2012) Sepsis In-hospital mortality
PSI (Fine NEJM 1997) Community-acquired pneumonia Low risk of 30-day mortality
qSOFA (Singer JAMA 2016) Sepsis In-hospital mortality
SCAP (Yandiola Chest 2009) Community-acquired pneumonia Adverse outcome*
SMART-COP (Charles Clin Infect Dis 2008) Community-acquired pneumonia Need for ventilator or vasopressor support
SOFA (Vincent Int Care Med 1996) Sepsis ICU mortality
Surgisphere (no definitive publication) covid-19 In-hospital mortality / critical illness**
Xie score (Xie MedRxiv 2020) covid-19 Mortality
*ICU admission, need for mechanical ventilation, severe sepsis, or treatment failure)
**Measured outcome unclear in online material
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Appendix 13. Operative characteristics of included risk stratification scores to predict mortality at 
reported cut-offs within validation cohorts.
Test TP TN FP FN Sensitivity Specificity PPV NPV
Surgisphere (>4) 4328 5597 7242 1526 73.9 43.6 37.4 78.6
Surgisphere (>7) 2544 9646 3193 3310 43.5 75.1 44.3 74.5
qSOFA (>1) 1346 12 015 1100 4601 22.6 91.6 55.0 72.3
qSOFA (>2) 198 13 041 74 5749 3.3 99.4 72.8 69.4
NEWS2 (>4) 3090 9014 3914 2760 52.8 69.7 44.1 76.6
NEWS2 (>6) 1736 11 259 1669 4114 29.7 87.1 51.0 73.2
SMART-COP (>2) 129 115 216 24 84.3 34.7 37.4 82.7
SMART-COP (>4) 49 281 50 104 32.0 84.9 49.5 73.0
SMART-COP (>6) 10 320 11 143 6.5 96.7 47.6 69.1
SCAP (≥10) 163 36 159 9 94.8 18.5 50.6 80.0
SCAP (≥20) 96 138 57 76 55.8 70.8 62.7 64.5
SCAP (≥30) 42 184 11 130 24.4 94.4 79.2 58.6
DL score (Low) 4020 4986 5892 1160 77.6 45.8 40.6 81.1
DL score (High) 3441 6462 4416 1739 66.4 59.4 43.8 78.8
CRB65 (=0) 5599 3636 9479 347 94.2 27.7 37.1 91.3
CRB65 (>2) 861 12 630 485 5085 14.5 96.3 64.0 71.3
DS-CRB65 (>1) 4815 6037 6618 965 83.3. 47.7 42.1 86.2
DS-CRB65 (>2) 2832 10 079 2576 2948 49.0 79.6 52.4 77.4
DS-CRB65 (>3) 1148 12 045 610 4632 19.9 95.2 65.3 72.2
CURB65 (>1) 4004 5537 4861 919 81.3 53.3 45.2 85.8
CURB65 (>2) 2092 8640 1758 2831 42.5 83.1 54.3 75.3
CURB65 (>3) 648 10 092 306 4275 13.2 97.1 67.9 70.2
A-DROP (≥3) 1864 9234 1175 3060 37.9 88.7 61.3 75.1
A-DROP (≥4) 448 10 236 173 4476 9.1 98.3 72.1 69.6
E-CURB65 (>2) 361 653 408 94 79.3 61.5 46.9 87.4
E-CURB65 (>4) 67 1030 31 388 14.7 97.1 68.4 72.6
PSI (>70) 123 44 185 5 96.1 19.2 39.9 89.8
PSI (>90) 113 91 138 15 88.3 39.7 45.0 85.8
PSI (>130) 73 172 57 55 57.0 75.1 56.2 75.8
Some included scores did not provide cut-off values. TP – True positive; TN - True negative; FP – False positive; FP – 
False positive; PPV – Positive predictive value; NPV – Negative predictive value. *Derived in covid-19 cohort 
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Appendix 14. Demographic and clinical characteristics for validation cohort after stratification by 
geography. 
Validation North dataset 
(n = 13 769)
Validation South dataset
(n = 8592)
Number of hospitals included 117 86
Mortality (%) 4287 (31.1) 2442 (28.4)
Age (years) <50 1599 (11.6) 1210 (14.1)
50-59 1561 (11.3) 1058 (12.3)
60-69 1877 (13.6) 1266 (14.7)
70-79 3198 (23.2) 1753 (20.4)
≥80 5534 (40.2) 3305 (38.5)
Sex at Birth Male 7359 (53.6) 4782 (55.7)
Female 6380 (46.4) 3798 (44.3)
Ethnicity White 11 098 (89.1) 5732 (77.9)
South Asian 4234 (3.5) 377 (5.1)
East Asian 54 (0.4) 86 (1.2)
Black 279 (2.2) 490 (6.7)
Other Ethnic Minority 590 (4.7) 677 (9.2)
Chronic cardiac disease  4548 (35.1) 2471 (32.3)
Chronic kidney disease 2453 (19.1) 1316 (17.4)
Malignant neoplasm  1387 (10.9) 800 (10.6)
Moderate or severe liver disease 294 (2.3) 140 (1.9)
Obesity (clinician defined)  1412 (12.3) 822  (12.1)
Chronic pulmonary disease (not 
asthma)
2499 (19.4) 1238 (16.3)
Diabetes (type 1 & type 2)  2659 (21.6) 1616 (22.4)
Number of comorbidities 0 2333 (17.6) 1583 (20.1)
1  3732 (28.1) 2381 (30.2)
≥2  7227 (54.3) 3921 (49.7)
Respiratory Rate 20.0 (7.0) 21.0 (8.0)
Oxygen saturation (%) 94.0 (5.0) 94.0 (6.0)
Systolic blood pressure (mmHg) 128.0 (33.0) 129.0 (33.0)
Diastolic blood pressure (mmHg) 73.0 (20.0) 73.0 (20.0)
Temperature (°C) 37.1 (1.5) 37.1 (1.5)
Heart Rate (bpm) 90.0 (27.0) 90.0 (27.0)
Glasgow Coma Score 15.0 (0.0) 15.0 (0.0)
Haemoglobin (g/L) 127.0 (31.0) 127.0 (31.0)
White cell count (109/L) 7.5 (5.3) 7.8 (5.4)
Neutrophil count (109/L) 5.7 (4.9) 6.0 (5.0)
Lymphocyte count (109/L) 0.9 (0.7) 0.9 (0.7)
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Validation North dataset 
(n = 13 769)
Validation South dataset
(n = 8592)
Platelet Count (109/L) 222.0 (125.2) 224.0 (128.0)
Sodium (mmol/L) 137.0 (7.0) 137.0 (6.0)
Potassium (mmol/L) 4.1 (0.8) 4.1 (0.7)
Total Bilirubin (mg/dL) 9.0 (8.0) 10.0 (7.0)
Urea (mmol/L) 7.4 (6.7) 7.3 (6.9)
Creatinine (µmol/L) 86.0 (57.0) 87.0 (56.0)
C-reactive protein (CRP) (mg/dL) 75.0 (115.0) 82.0 (127.0)
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Appendix 14. Sensitivity analysis of discriminatory performance for risk stratification scores after 
stratification of validation cohort by geography to predict inpatient mortality in patients hospitalised 
with covid-19.
Validation North (N = 13 769) Validation South (N = 8592)
N AUROC (95% CI) N AUROC (95% CI)
SOFA 42 0.620 (0.443-0.797) 155 0.611 (0.514-0.707)
qSOFA 12250 0.624 (0.614-0.634) 7111 0.622 (0.609-0.635)
SMARTCOP 206 0.629 (0.554-0.704) 6984 0.624 (0.610-0.638)
Surgisphere* 12001 0.635 (0.624-0.645) 7009 0.642 (0.628-0.657)
SCAP 189 0.661 (0.584-0.738) 6355 0.659 (0.644-0.673)
NEWS 12064 0.662 (0.651-0.672) 7110 0.681 (0.669-0.693)
DL score* 9989 0.676 (0.665-0.687) 181 0.689 (0.610-0.769)
CRB65 12250 0.685 (0.676-0.694) 280 0.694 (0.623-0.765)
COVID-GRAM* 522 0.704 (0.659-0.749) 6875 0.709 (0.696-0.721)
CURB65 9815 0.723 (0.713-0.733) 716 0.709 (0.667-0.752)
DS-CRB65 11841 0.723 (0.714-0.732) 5743 0.717 (0.704-0.730)
Xie score* 688 0.737 (0.697-0.777) 1064 0.727 (0.693-0.761)
A-DROP 9814 0.740 (0.730-0.750) 5756 0.729 (0.716-0.742)
PSI 212 0.742 (0.675-0.810) 148 0.738 (0.649-0.827)
E-CURB65 621 0.778 (0.742-0.813) 931 0.757 (0.725-0.789)
4C Mortality Score 8938 0.778 (0.768-0.788) 5458 0.769 (0.756-0.782)
Machine learning 
comparison (XGBoost) -
0.785 (0.777-0.793) - 0.769 (0.758-0.779)
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Appendix 15. Risk of bias assessment using PROBAST checklist.
Domain Item Development ROB Validation ROB
1.1 Were appropriate data 
sources used, e.g. 
cohort, RCT or nested 
case-control study data?
Prospective longitudinal cohort design. 
Prespecified research database and 
predefined follow-up (hospital 
inpatient). Protocol for model 
development specified a priori
+ Prospective longitudinal cohort 
design. Prespecified research 
database and predefined follow-up 
(hospital inpatient)
+
Participants
1.2 Were all inclusions and 
exclusions of 
participants 
appropriate?
All patients within cohort included + All patients within cohort included +
2.1 Were predictors defined 
and assessed in a similar 
way for all participants?
Predictors defined and assessed in the 
same way for all study participants
+ Predictors defined and assessed in 
the same way for all study 
participants
+
2.2 Were predictor 
assessments made 
without knowledge of 
outcome data?
Prospective cohort design - prognostic 
predictors were assessed at time of 
admission and before outcome 
occurrence
+ Prospective cohort design - 
prognostic predictors were assessed 
at time of admission and before 
outcome occurrence
+
Predictors
2.3 Are all predictors 
available at the time the 
model is intended to be 
used?
All predictors available within the first 
few hours of admission to hospital
+ All predictors available within the 
first few hours of admission to 
hospital
+
3.1 Was the outcome 
determined 
appropriately?
Objective outcome (mortality) used + Objective outcome (mortality) used +
3.2 Was a pre-specified or 
standard outcome 
definition used?
Yes - mortality + Yes - mortality +
3.3 Were predictors 
excluded from the 
outcome definition?
Outcome determined without 
information about predictors
+ Outcome determined without 
information about predictors
+
3.4 Was the outcome 
defined and determined 
in a similar way for all 
participants?
Outcome (mortality) defined and 
determined in the same way for all 
study participants
+ Outcome (mortality) defined and 
determined in the same way for all 
study participants
+
3.5 Was the outcome 
determined without 
knowledge of predictor 
information?
Outcome determined without 
information about predictors
+ Outcome determined without 
information about predictors
+
Outcome
3.6 Was the time interval 
between predictor 
assessment and 
outcome determination 
appropriate?
Time interval between predictor 
measurement and outcome clinically 
appropriate (in-hospital mortality)
+ Time interval between predictor 
measurement and outcome 
clinically appropriate (in-hospital 
mortality)
+
Analysis
4.1 Were there a 
reasonable number of 
participants with the 
outcome?
High events per variable (>20) + High events per variable (>20) and 
>100 events overall
+
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4.2 Were continuous and 
categorical predictors 
handled appropriately?
Continuous variables examined for 
nonlinearity using thin-plate splines. 
Optimal cut-points were selected using 
the methods of Barrio et al.
+ Use of same predictors and scale as 
derived model
+
4.3 Were all enrolled 
participants included in 
the analysis?
All participants included in the analysis + All participants included in the 
analysis
+
4.4 Were participants with 
missing data handled 
appropriately?
Multiple imputation methods (MICE) 
used for missing data
+ Multiple imputation methods 
(MICE) used for missing data
+
4.5 Was selection of 
predictors based on 
univariable analysis 
avoided?
Univariable analysis not performed + N/A +
4.6 Were complexities in 
the data (e.g. censoring, 
competing risks, 
sampling of controls) 
accounted for 
appropriately?
Model developed using a full cohort 
approach and short-term follow-up 
(inpatient mortality)
+ Full cohort approach used and 
short-term follow-up (inpatient 
mortality)
+
4.7 Were relevant model 
performance measures 
evaluated 
appropriately?
Model calibration and discrimination 
(AUROC) assessed, together with 
classification measures
+ Model calibration and 
discrimination (AUROC) assessed, 
together with classification 
measures
+
4.8 Were model overfitting 
and optimism in model 
performance accounted 
for?
10-fold cross-validation performed
using least absolute shrinkage and
selection operator (LASSO) logistic
regression
+ N/A +
4.9 Do predictors and their 
assigned weights in the 
final model correspond 
to the results from 
multivariable analysis?
Predictors and regression coefficients 
of the final developed model, including 
intercept, are fully reported and 
correspond with the 4C Mortality 
Score index values
+ N/A +
*ROB – Risk of Bias; + indicates low ROB/low concern regarding applicability; − indicates high ROB/high concern
regarding applicability; and ? indicates unclear ROB/unclear concern regarding applicability.
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